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http://dx.doi.org/10.1016/j.ccell.2014.11.007SUMMARYBYL719, which selectively inhibits the alpha isoform of the phosphatidylinositol 3-kinase (PI3K) catalytic
subunit (p110a), is currently in clinical trials for the treatment of solid tumors, especially luminal breast can-
cers with PIK3CAmutations and/or HER2 amplification. This study reveals that, even among these sensitive
cancers, the initial efficacy of p110a inhibition is mitigated by rapid re-accumulation of the PI3K product PIP3
produced by the p110b isoform. Importantly, the reactivation of PI3K mediated by p110b does not invariably
restore AKT phosphorylation, demonstrating the limitations of using phospho-AKT as a surrogate tomeasure
PI3K activation. Consistently, we show that the addition of the p110b inhibitor to BYL719 prevents the PIP3
rebound and induces greater antitumor efficacy in HER2-amplified and PIK3CA mutant cancers.INTRODUCTION
Phosphatidylinositol 3-kinase (PI3K) lipid kinases promote cell
growth and survival of many cancer types, including breast can-
cers that have genetic activation of this pathway in up to 70% of
cases (Hernandez-Aya and Gonzalez-Angulo, 2011). The class
IA PI3Ks are holoenzymes consisting of a regulatory subunit
(p85) bound to one of three possible catalytic subunits, p110a
(encoded by PIK3CA), p110b, and p110d. All class IA PI3Ks
are activated by recruitment to phosphotyrosine peptides,
such as those on receptor tyrosine kinases (RTKs) and adaptors
(e.g., IRS-1), via the SH2 domains of p85. However, p110b is the
only member that can also be activated by G protein-coupled re-
ceptors (GPCRs). Class I PI3Ks function by phosphorylating theSignificance
Clinical development of PI3K inhibitors is underway, and there
hibitors that may have a greater therapeutic index. We found t
HER2 amplification were among those more sensitive to the se
cell lines, PI3K signaling was rapidly restored after the initial r
Because BYL719 is currently tested in the clinic for PIK3CA m
may limit its efficacy in the clinic. Importantly, we showed tha
and potentiated the antitumor effects of p110a inhibitor in vivD-3 position of the inositol ring of phosphatidylinositol (4,5)-bi-
sphosphate (PI(4,5)P2) to generate the second messenger phos-
phatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 activates its
effectors, such as AKT, by recruiting them to the membrane
via their pleckstrin homology (PH) domains (Engelman, 2009).
Due to the technical challenges of directly measuring the PI3K
product, PIP3, the phosphorylation level of the downstream
effector AKT has historically been used to indirectly assess the
activity of class I PI3K. Although this approach has proven to
be rather useful, it is based on the assumption that this readout
is always proportional to PIP3 levels, which may apply to only a
limited range of PI3K activation levels and/or in specific cellular
contexts. For instance, AKT phosphorylation correlates poorly
with PIK3CA mutation status in some types of breast canceris emerging enthusiasm for using isoform-specific PI3K in-
hat breast cancer cells harboring PIK3CA mutations and/or
lective p110a inhibitor BYL719. However, even among these
esponse to BYL719 via the activation of the p110b isoform.
utant breast cancer, this reactivation is critical because it
t the p110b inhibitor was effective in blocking PIP3 rebound
o.
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the use of AKT phosphorylation as readout of PI3K activity ig-
nores other potentially relevant downstream targets of PI3K.
For example, one report demonstrated that PI3K controls cell
viability of some PIK3CA mutant breast cancers through SGK3
in an AKT-independent manner (Vasudevan et al., 2009). More
recently, it has been demonstrated that in luminal breast cancers
PI3K regulates Rac-ERK signaling independently of AKT via the
PH-domain containing Rac guanine exchange factor, P-Rex1
(Ebi et al., 2013).
Over the past several years, significant investment has been
made into the rational development of both isoform-specific
and pan-PI3K inhibitors. However, it is unclear which type of
PI3K inhibitor will bemost effective among the different subtypes
of breast cancer. One potential limitation of pan-PI3K inhibitors
is the toxicity that may emerge when all PI3K isoforms are sup-
pressed. Thus, if a single PI3K isoform is driving cell proliferation
in a specific cancer, then isoform-specific inhibitors may exhibit
a greater therapeutic window, and thus permit more complete
inhibition of the critical isoform. Among all class IA members,
p110a is the isoform predominantly mutated in cancers (Sam-
uels et al., 2004) and has a prominent role in controlling cell
growth in solid malignancies (Bader et al., 2006; Foukas et al.,
2006; Zhao et al., 2006). For these reasons, the a-specific inhib-
itor BYL719 is currently being tested in clinical trials (Juric and
Baselga, 2012; Juric et al., 2012). Because preclinical data indi-
cate that breast cancers are particularly sensitive to pan-PI3K
pathway inhibitors (Faber et al., 2009; O’Brien et al., 2010), we
explored which genetically defined breast cancers were more
sensitive to BYL719 and if these tumors were solely dependent
on p110a.
RESULTS
Reactivation of PI3K Signaling following Inhibition with
a-Selective Inhibitor BYL719 in HER2-Amplified Breast
Cancers
To identify the breast tumors most sensitive to the selective
p110a inhibitor, BYL719, we tested the effect of this drug on
cell proliferation in a large panel of breast cancer cell lines. As
shown in Figure 1A (Table S1 available online), breast cancer
cell lines harboring mutations in PIK3CA and/or HER2 amplifica-
tions were significantly more sensitive to the antiproliferative ef-
fects of BYL719 than breast cancer cells that are wild-type for
both genes. These data were further supported by analysis in a
larger panel of 321 cancer cell lines (Figure S1A and Table S2)
and are in agreement with results of previous reports (Fritsch
et al., 2014; Huang et al., 2012). To test whether p110a inhibition
alone was sufficient to completely abrogate PI3K-AKT signaling,
time-course experiments using BYL719 in multiple PIK3CA hot-
spot mutant orHER2-amplified breast cancer cell lines were per-
formed.While BYL719 effectively suppressed AKT over the 24 hr
time course in PIK3CA mutant cells (HER2 wild-type), a more
pronounced rebound of AKT phosphorylation was observed af-
ter 24 hr in the HER2-amplified cells (Figure 1B). This rebound of
AKT activation after 24 hr in the HER2-amplified cells is due to a
biological effect rather than degradation or efflux of the p110a in-
hibitor, because similar rebound of AKT signaling occurred
despite the addition of fresh drug to the media of cells after98 Cancer Cell 27, 97–108, January 12, 2015 ª2015 Elsevier Inc.22 hr (Figure 1C). Furthermore, the intracellular concentration
of BYL719 was the same at 1 and 24 hr after treatment (Fig-
ure S1B). Accordingly, in HER2-amplified cells, AKT signaling
completely recovered at longer time points (48 and 72 hr), while
it remained more effectively suppressed in PIK3CAmutant cells
(Figure S1C). Notably, BYL719 treatment did not change expres-
sion levels of the PIP3 phosphatase PTEN (Figure S1D), suggest-
ing that the restoration of AKT signaling is not due to alteration of
the phosphatase expression.
Validation of a Nonradioactive Method to Directly
Measure PI3K Activity
Because AKT activation may also occur via PI3K-independent
mechanisms (Guo et al., 2011), we aimed to determine if the re-
activation of AKT phosphorylation was due to restored produc-
tion of PIP3 despite the presence of BYL719. To directly measure
PIP3 levels, an ELISA kit, which has recently been developed to
quantify the levels of different phosphoinositides, was utilized.
Since PI(4,5)P2 is the most abundant phosphoinositide (Guillou
et al., 2007) and its levels are not influenced by PI3K activity
(Condliffe et al., 2005), PI(4,5)P2 levels were used as a control
for total phosphoinositides, as previously described (Clark
et al., 2011; Guillou et al., 2007). PIP3/PI(4,5)P2 ratios were
measured after treatment with different inhibitors to test the
specificity and reliability of this method under multiple condi-
tions. First, BT474 and T47D cells were treated with the pan-
PI3K inhibitor, GDC-0941; as expected, there was potent
suppression of the PIP3/PI(4,5)P2 ratio (Figure 2A). Importantly,
comparable results and equivalent range of suppression were
observed when the PIP3/PI(4,5)P2 ratio was measured with
metabolic labeling of cells with [3H] inositol followed by high-per-
formance liquid chromatography (HPLC) (Figure 2B), a classical
technique for phosphoinositide measurement (Guillou et al.,
2007). To further assess the reliability of this method for PIP3
quantification, T47D cells were treated with varying concentra-
tions of BYL719 for 1 hr. As shown in Figure 2C, this treatment
led to a dose-dependent decrease of PIP3 that correlated well
with the reduction of AKT phosphorylation. Then, PIP3 levels
were determined under a condition in which an increase of
PIP3 levels was expected. T47D cells were exposed for 24 hr
to different concentrations of AZD8055, an mTORC1/2 catalytic
inhibitor. Under these conditions, PIP3 levels dramatically
increased, indicating the stimulation of PI3K activity (Figure 2D,
left), in accordance with release of the well-establishedmTORC1
negative feedback loops leading to reactivation of PI3K signaling
(O’Reilly et al., 2006; Rodrik-Outmezguine et al., 2011). Accord-
ingly, the mTORC2-dependent AKT phosphorylation on Serine
473 was completely abrogated whereas the PI3K/PDK1-depen-
dent AKT phosphorylation on Threonine 308 was induced by
derepression of the negative feedback (Figure 2D, right), in
agreement with the PIP3 measurements. Finally, we compared
PIP3 levels using different PI3K inhibitors. To do so, BT474 and
U87MG cells were treated for 1 hr with BYL719 and a pan-
PI3K inhibitor GDC-0941. As expected, in BT474 cells, BYL719
was sufficient to downregulate PIP3 levels, while in U87MG cells,
which are PTEN null and largely p110b-dependent (Wee et al.,
2008), GDC-0941, but not BYL719, suppressed PIP3 levels (Fig-
ure 2E). All together, these data demonstrate that this method
consistently and reliably quantifies PIP3 levels.
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Figure 1. Rebound of Phospho-AKT Occurs after 24 hr Treatment with Selective p110a Inhibitor in HER2-Amplified Cell Lines
(A) Effects of BYL719 on proliferation in a panel of 36 breast cancer cell lines. HER2-amplified versus HER2WT, Fishers test p = 0.0363; PIK3CAmutant versus
PIK3CA WT, Fishers test p = 0.0188.
(B) HER2-amplified (upper) and PIK3CA hot-spot mutant (lower) cell lines were treated with 1 mM BYL719 for the indicated period of time. Lysates were im-
munoblotted to detect the indicated proteins.
(C) The indicated cell lines were treated with 1 mMBYL719 for indicated period of time (fresh drug was added after 22 hr). Lysates were immunoblotted to detect
the indicated proteins.
See also Figure S1 and Tables S1 and S2.
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PIP3 Levels Reveal p110b Role in Breast CancerThe p110b Isoform Is Responsible for the Reactivation
of PIP3 Signaling after Treatment with BYL719 in HER2-
Amplified Breast Cancers
Using the ELISA assay, PIP3 levels were measured in HER2-
amplified cells following treatment with BYL719 for 1 or 24 hr.
In accordance with AKT phosphorylation (Figure 1B), PIP3 levels
were suppressed at 1 hr, but were partially restored after 24 hr
treatment (Figure 2F), indicating that this reactivation of AKT
was due to a rebound in PIP3 despite the continued presenceof BYL719. This AKT reactivation diminished the impact of sin-
gle-agent BYL719 on cell viability as the AKT inhibitor MK2206
improved the efficacy of BYL719 in blocking cell growth and
inducing apoptosis (Figures S2A and S2B).
Because BYL719 is a selective p110a inhibitor, we hypothe-
sized that the restored PIP3 levels may be due to activation of
another p110 isoform. To investigate if other p110 isoforms
were responsible for this rebound of AKT phosphorylation, we
utilized p110b and p110d isoform-selective inhibitors (TGX-221Cancer Cell 27, 97–108, January 12, 2015 ª2015 Elsevier Inc. 99
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Figure 2. Validation of ELISA Kit to Measure the Ratio of PIP3/PI(4,5)P2
(A) Phospholipids were isolated from cells treated with DMSO or 1 mM GDC-0941 for 1 hr and relative PIP3 and PI(4,5)P2 levels were quantified by ELISA. Each
data point represents the average of three independent experiments, each carried out in triplicate. For normalization, the PIP3/PI(4,5)P2 ratio was set to 100% for
DMSO treated cells.
(B) Phospholipids were isolated from cells treated as in (A) and measured with HPLC analysis after metabolic labeling of the cells for 48 hr.
(C and D) T47D cells were treated with indicated concentrations of BYL719 for 1 hr (C) or AZD8055 for 24 hr (D). Phospholipids were isolated and PIP3 and PI(4,5)
P2 levels were quantified by ELISA (left) or cell lysates were immunoblotted to detect the indicated proteins (right).
(E) Cells were treated with 1 mM BYL719 or 1 mM GDC-0941 for 1 hr and relative PIP3 and PI(4,5)P2 levels were quantified by ELISA.
(F) Phospholipds were isolated from cells treated with 1 mMBYL719 for indicated time and relative PIP3 and PI(4,5)P2 levels were quantified by ELISA. p < 0.05 by
Student’s t test.
All error bars in this figure represent ± SEM. See also Figure S2.
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selectively discriminate among different isoforms (Huang et al.,
2012; Kim et al., 2009; Utermark et al., 2012). Specificity was
confirmed in the PTEN-deficient PC3 cells, in which the activa-
tion of AKT is primarily mediated by p110b, and theHER2-ampli-
fied BT474 cells, in which the activation of AKT is primarily medi-
ated by p110a (Figure S3A). The SKBR3 and BT474 cells were
treated with different combinations of these isoform-selective in-
hibitors for 6 and 24 hr (Figure 3A). The combination of BYL719
and TGX-221 effectively mitigated the rebound of AKT phos-
phorylation after 24 hr (Figure 3A and Figure S3B). Accordingly,
this combination also blocked the re-accumulation of PIP3 (Fig-
ure 3B). These results were recapitulated by siRNA-mediated
knockdown of p110b in the presence of BYL719 (Figure 3C).
Thus, p110b is responsible for the rebound in PIP3 levels and
the reaccumulation of AKT phosphorylation in HER2-amplified
cancers treated with a p110a-specific inhibitor.
We next aimed to determine molecular mechanisms underly-
ing p110b-induced PIP3 production following initial inhibition of
p110a and to identify upstream activators of p110b. ERBB3 is
a receptor that heterodimerizes with HER2 and drives PI3K acti-
vation inHER2-amplified breast cancer cells (Arteaga and Engel-
man, 2014). Immunoprecipitation studies revealed increased
recruitment of p110b to ERBB3 following 24 hr of treatment
with BYL719 (Figure 3D), thus accounting for the induction of
p110b-dependent production of PIP3. The increased association
between p110b and ERBB3 was likely induced by increased
tyrosine phosphorylation and total levels of ERBB3 promoted
by PI3K inhibition (Figure 3D), through several feedbacks as pre-
viously reported (Chakrabarty et al., 2012; Chandarlapaty et al.,
2011). Accordingly, cotreatment with BYL719 and the HER2 in-
hibitor lapatinib blocked ERBB3 phosphorylation (Figures 3E
and 3F). This led to the loss of p110b recruitment (Figure 3E)
and the block of the rebound of AKT activation observed 24 hr
after treatment with BYL719 alone (Figure 3F). Similarly,
siRNA-mediated downregulation of ERBB3 (Figure S3C) or inac-
tivation of ERBB3 through LJM716, a specific antibody that
blocks ERBB3 activation (Garrett et al., 2013) (Figure 3G),
impaired the re-accumulation of AKT phosphorylation. Because
p110b can be activated also by GPCRs, cells were treated with
pertussis toxin, which inhibits the Gi subunit downstream of
GPCRs. This treatment did not block reactivation of AKT (Fig-
ure 3H), suggesting that HER2 and ERBB3 have a more promi-
nent role in activating p110b and AKT in HER2-amplified breast
cancer cells. Taken together, these data suggest that although
inhibition of p110a potently suppresses the PI3K pathway after
1 hr, concomitant inhibition of p110b may be necessary to
achieve complete and sustained inhibition of PI3K signaling in
HER2-amplified cells.
p110b Activation Mitigates the Growth Arrest and
Apoptosis Induced by BYL719 in HER2-Amplified and
PIK3CA Mutant Models
We next determined if the combination of the p110a and b inhib-
itors demonstrated an additive effect in blocking cell growth and
inducing apoptosis in HER2-amplified breast cancers. Long-
term cell viability and apoptosis (Figure 4A) assays revealed
that dual inhibition of p110a and p110b was more effective
than single agent BYL719 in HER2-amplified breast cancers,despite the finding that TGX-221 had no detectable effects on
cell viability and growth as a single agent. As a control, we
included PIK3CA mutant breast cancers, which had not
displayed a substantial rebound of phospho-AKT following treat-
ment of BYL719 (Figure 1B; Figure S1C). To our surprise, com-
bined p110a and p110b inhibition also impaired cell viability to
a greater extent than inhibition of p110a alone in two of the three
PIK3CA mutant breast cancer cell lines examined. This was
initially unexpected because, unlike the HER2-amplified breast
cancers, phospho-AKT levels did not substantially rebound
in PIK3CA mutant cells for up to 72 hr after treatment with
BYL719 (Figure S1C). Accordingly, addition of the p110b inhibi-
tor did not lead to more pronounced suppression of phosphory-
lation of AKT or its substrates in thesePIK3CAmutant cancer cell
lines (Figure 4B). However, measurement of PIP3 levels revealed
that BYL719 did not fully suppress PIP3 levels in PIK3CAmutant
cells, especially after 24 hr, and combined inhibition of p110a
and p110b resulted in stronger reduction of PIP3 levels than
BYL719 alone (Figure 4C). Because p110b has been shown to
induce phosphorylation of nuclear AKT (Kumar et al., 2011), we
determined if inhibition of p110b affected AKT signaling specif-
ically in the nucleus, which may have been missed in assess-
ments of AKT phosphorylation in whole cell lysates (Figure 4B).
However, in the PIK3CA mutant cell line MCF7, p110b did
not control AKT phosphorylation in either the cytoplasm or the
nucleus (Figure S4A). Thus, these findings demonstrate that
p110b contributes to PIP3 levels in PIK3CAmutant breast cancer
cells, and inhibition of p110b augments the effects of p110a in-
hibition on cell viability in an AKT-independent manner in these
cells.
To identify the mechanism underlying p110b activation in
PIK3CA mutant cells, lysates from cells treated for 24 hr with
BYL719 were hybridized to p-RTK arrays (Figure S4B). Treat-
ment with p110a inhibitor induced increased phosphorylation
of HER2 and ERBB3 in T47D cells whereas no changes were
observed in the p-RTK arrays probed with the MCF7 lysates.
We also specifically probed for the RTKs previously found to
be activated following treatment with PI3K inhibitor (Chakra-
barty et al., 2012) (Figure 4D). These results confirmed the in-
duction of HER2 and ERBB3 phosphorylation in T47D cells.
However, in MCF7 cells, BYL719 led to lower levels of total
insulin-like growth factor 1 receptor (IGF1R) (Figure 4D). We
speculated that this might possibly reflect an increase in its
phosphorylation and activation. To test this hypothesis, we
immunoprecipitated the IGF1R-adaptor IRS1 and assessed its
phosphorylation. An increased in tyrosine phosphorylation of
IRS1 after BYL719 treatment was observed (Figure S4C), sug-
gesting that BYL719 indeed induced the activation of the
IGF1R-dependent signaling pathway in MCF7 cells. To test if
HER2/ERBB3 and IGF1R signaling were responsible for the
activation of p110b activation in T47D and MCF7 cells, respec-
tively, we measured PIP3 levels after treating both cell lines with
BYL719 alone, or in combination with the anti-ERBB3 antibody
LJM716, the IGF1R inhibitor NVP-AEW541, or the fibroblast
growth factor receptor inhibitor NVP-BGJ398 (Figure 4E). In
T47D cells, only the combination of BYL719 and LJM716
blocked the re-accumulation of PIP3 similarly to the combina-
tion of p110a and p110b inhibitors, whereas, in MCF7 cells,
the rebound of PIP3 was prevented by the combination ofCancer Cell 27, 97–108, January 12, 2015 ª2015 Elsevier Inc. 101
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Figure 3. Inhibition of p110b Blocks the Rebound of AKT Phosphorylation and PIP3 Levels in HER2-Amplified Cell Lines
(A) The indicated HER2-amplified cell lines were treated with p110a inhibitor BYL719 (1 mM), p110b inhibitor TGX-221 (1 mM), and p110d inhibitor IC87114 (1 mM)
or combinations of these inhibitors for the indicated times. Lysates were immunoblotted to detect the indicated proteins.
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were quantified by ELISA. Each data point is the average ± SEM (p < 0.05 by Student’s t test).
(C) Cells were transfected with control (Scr) or p110b-targeted siRNA for 48 hr, followed by treatment with BYL719 (1 mM) for an additional 24 hr. Lysates were
immunoblotted to detect the indicated proteins.
(D and E) BT474 cells were treated with 1 mM BYL719 alone for different durations of time (D) or with 1 mM Lapatinib (LAP) for 24 hr (E) and lysates were
immunoprecipitated with ERBB3 antibody. Precipitates were analyzed by western blot with the indicated antibodies.
(F) Cells were treated with indicated drugs at 1 mM for 24 hr. Lysates were immunoblotted to detect the indicated proteins.
(legend continued on next page)
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report demonstrated that IGF1R inactivation sensitizes MCF7
cells to PI3K inhibitors (Chakrabarty et al., 2012). These data
suggest that p110b activation is also driven by RTKs in PIK3CA
mutants. However, pertussis toxin also prevented the rebound
of PIP3 after BYL719 treatment (Figure 4F), suggesting that
input from both RTKs and GPCRs is required for p110b engage-
ment and activation in PIK3CA mutant models.
Combination of p110a and p110b Inhibition Induces
Tumor Regression In Vivo
These findings led us to test the efficacy of combined p110a and
p110b inhibitors in vivo. Because TGX-221 cannot be used for
in vivo studies, we used the structurally related p110b selective
inhibitor KIN-193 (Ni et al., 2012). Dose-response assays
in vitro confirmed comparable sensitivity of PTEN-deficient
LNCaP cells to TGX-221 and KIN-193, as well as a similar lack
of potency in BT474 cells (Figure S5A). Whereas BT474 xeno-
grafts primarily exhibited static tumor growth when treated
with BYL719 alone, tumors regressed when treated with the
combination of p110a and p110b inhibitors (Figure 5A and Fig-
ure S5B). Pharmacodynamic studies of the drug-treated tumors
were consistent with the in vitro results. Both phospho-AKT and
PIP3 levels were partially restored following BYL719 administra-
tion in HER2-amplified tumors (Figures S5C and S5D). However,
the addition of the p110b inhibitor led to greater suppression of
AKT phosphorylation than BYL719 treatment alone (Figure 5B).
To further assess the activity of combination of p110a and
p110b inhibitor, we used a genetically engineered mouse model
(GEMM) of HER2-amplified breast cancer. Consistent with the
findings in the human xenograft model, both BYL719 and
GSK2636771, a structurally unrelated p110b inhibitor currently
in clinical trials, slowed tumor growth but only the combination
induced tumor shrinkage (Figure 5C).
To validate our in vitro findings in PIK3CAmutant cells, we also
tested MCF7 tumor xenografts. MCF7 tumors regressed only
with the combination of p110a and p110b inhibitors (Figure 5D
and Figure S5E). In contrast to the analyses of the HER2-ampli-
fied xenograft tumors, lysates from MCF7 tumors revealed that
suppression of AKT phosphorylation was not further increased
by the addition of the p110b inhibitor (Figure 5E), consistent
with the in vitro findings (Figure 4B). However, PIP3 levels were
more effectively suppressed in MCF7 tumors treated with the
combination in comparison to BYL719 alone (Figure 5F), sup-
porting the notion that PIP3 may serve as an informative
biomarker to more fully assess PI3K inhibition and efficacy
in vivo.
DISCUSSION
In this study, we observed that p110a inhibition alone is not suf-
ficient to completely suppress PI3K activity in HER2-amplified
and PIK3CAmutant breast cancer cells, even though these can-
cers are among the most sensitive to single-agent p110a-spe-(G) Cells were treated with 1 mM BYL719 alone or in combination with 10 mg/ml
proteins.
(H) Cells were treated or not with pertussis toxin (PTX) 100 ng/ml and the indicated
See also Figure S3.cific inhibitors. Although p110a is the major isoform responsible
for PI3K signaling in these cancers, p110b activation partially
recovered PIP3 levels within 24 hr of BYL719 treatment. In
HER2-amplified cancers, this led to reactivation of AKT, but in
PIK3CAmutant cancers, it did not. However, in both breast can-
cer models, concomitant inhibition of p110a and p110b induced
greater antitumor activity.We speculate that this p110b-depend-
ent rebound of PIP3 requires several hours to manifest for two
main reasons: (1) the time required for maximal BYL719-depen-
dent release of the negative feedbacks leading to tyrosine phos-
phorylation of PI3K activators (e.g., ERBB3) and subsequent
p110b recruitment, and (2) since p110b is a relatively inefficient
enzyme in comparison to p110a (Beeton et al., 2000), PIP3 accu-
mulation can only be observed after sufficient time following
activation. Although p110b has been identified as the primary
PI3K isoform driving PI3K signaling in PTEN null tumors
(Jia et al., 2008; Ni et al., 2012), the experiments in this study
suggest that p110b activation also promotes the viability of
p110a-driven breast cancers following treatment with p110a-s-
pecific inhibitors.
In vivo, p110a inhibition blocked tumor growth but did not
induce tumor shrinkage in either the HER2-amplified or
PIK3CA mutant xenograft models. Interestingly, early reports
from clinical trials showed that, even among patients whose
cancers harbor PIK3CA mutations, BYL719 did not induce re-
gressions in the majority of cases (Juric and Baselga, 2012;
Juric et al., 2012), consistent with our observation that p110a
inhibition alone does not cause tumor shrinkage in the PIK3CA
mutant MCF7 tumors. Surprisingly, two structurally distinct
p110b inhibitors showed an effect as single agents on the
growth of the HER2 amplified tumors in vivo (both in BT474
xenograft and GEMM model overexpressing HER2) despite
the lack of any antiproliferative effects in vitro. This is consis-
tent with previous reports showing that mice expressing a
catalytically inactive isoform of p110b showed slower tumor
growth in a HER2-driven model (Ciraolo et al., 2008) and that
p110b inhibition causes modest but significant reduction of tu-
mor growth in HER2-induced murine cancer model (Utermark
et al., 2012). It is possible that some of the effects observed
in vivo with the p110b inhibitor are non-cell-autonomous, or
that specific upstream activating mechanisms render p110b
more relevant in vivo. Importantly, tumor regressions resulted
from concomitant inhibition of p110a and p110b in the
GEMM overexpressing HER2, and HER2-amplified and
PIK3CA mutant xenograft models. We believe it might be
beneficial to combine two isoform-selective inhibitors instead
of using a pan-PI3K inhibitor, as the currently available pan-
PI3K inhibitors do not equally block all p110 isoforms. For
example, the pan-PI3K inhibitor GDC-0941 is equipotent
against p110a and p110d, but displays only modest (10-fold
less) activity against p110b (Raynaud et al., 2009). Accordingly,
GDC-0941 failed to induce tumor regression in MCF7 xeno-
graft (Ebi et al., 2013), whereas a combination of BYL719
and KIN-193 resulted in remarkable tumor shrinkageLJM716 (LJM) for 24 hr. Lysates were immunoblotted to detect the indicated
drug(s) for 24 hr. Lysates were immunoblotted to detect the indicated proteins.
Cancer Cell 27, 97–108, January 12, 2015 ª2015 Elsevier Inc. 103
D
M
S
O
B
Y
L 
B
Y
L+
LJ
M
B
Y
L+
A
E
W
B
Y
L+
B
G
J0
20
40
60
80
100
120
p<0.05
PI
P3
/P
I(4
,5
)P
2 
(%
)
D
M
S
O
B
Y
L 
B
Y
L+
TG
X
 
B
Y
L+
P
TX
0
20
40
60
80
100
120
p<0.05
PI
P3
/P
I(4
,5
)P
2 
(%
)
D
M
S
O
B
Y
L 
B
Y
L+
TG
X
 
B
Y
L+
P
TX
0
20
40
60
80
100
120
PI
P3
/P
I(4
,5
)P
2 
(%
)
p<0.05
D
M
S
O
B
Y
L 
B
Y
L+
LJ
M
B
Y
L+
A
E
W
B
Y
L+
B
G
J0
20
40
60
80
100
120
p<0.01
PI
P3
/P
I(4
,5
)P
2 
(%
)
A
B T47D MCF7 
p-GSK3 /
p-AKT S473
 p-AKT T308
AKT
p-ATPCL
PTEN
p-PRAS40
T47D MCF7
IGF1R
IR
FGFR1
p-ERBB3
ERBB3
p-HER2
HER2
BYL719 (24 hr) - + - +
ACTIN
D E T47D
MCF7 MCF7
T47D
BT474 SKBR3 AU565 MCF7 KPL-1 T47D
0
10
20
30
40
50
60
70
80
90
100
110
120
HER2 amplified PIK3CA hot-spot mutant
C
el
l v
ia
bi
lit
y 
(%
 o
f u
nt
re
at
ed
)  
BT474 SKBR3 AU565 MCF7 BT20 T47D
0
5
10
15
20 BYL
TGX
BYL+TGX
HER2 amplified PIK3CA hot-spot mutant
C MCF7
FT47D
p<0.01 p<0.05 
p<0.05 .05 
DM
SO BY
L 
BY
L 
TG
X
BY
L+
TG
X 
0
25
50
75
100
125
150
24 hrs1 hr
p<0.05
PI
P3
/P
I(4
,5
)P
2 
(%
)
DM
SO BY
L 
BY
L 
TG
X
BY
L+
TG
X 
0
25
50
75
100
125
150
24 hrs1 hr
p<0.01
PI
P3
/P
I(4
,5
)P
2 
(%
)
Figure 4. p110b Contributes to Cell Growth and Survival
(A) Cells were treated with 1 mM BYL719, 1 mM TGX-221, or both for 14 days and cell viability was determined by Syto60 staining (left) or for 72 hr and the
percentage of cells undergoing apoptosis was measured by annexin V positivity (right). Because BT-20 cells did not survive when seeded at low density, they
were not assayed for viability.
(B) Cells were treated with DMSO, 1 mM BYL719, 1 mM TGX-221, or the combination for 24 hr and lysates were immunoblotted to detect the indicated proteins.
(C) Cells were treated as (B) and PIP3 and PI(4,5)P2 levels were quantified by ELISA. p < 0.05 by Student’s t test.
(D) Cells were treated with 1 mM BYL719 for 24 hr and lysates were immunoblotted to detect the indicated proteins.
(legend continued on next page)
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PIP3 Levels Reveal p110b Role in Breast Cancer(Figure 5D). For this reason, the combination of two selective
and potent isoform-specific inhibitors may have a better ther-
apeutic window by maximally inhibiting p110a and p110b,
while sparing the toxicities associated with inhibiting other
PI3K isoforms. The article by Schwartz et al. (2014) in this issue
of Cancer Cell demonstrates that p110a inhibitor adds to the
efficacy of p110b inhibitor in PTEN-deficient cancers further
supporting the potential value of targeting both isoforms also
in PTEN-deficient contexts. Together, these findings point to
the value of inhibiting both isoforms in cancers because inhibi-
tion of only one p110 isoform leads to the activation of the
other isoform. Perhaps, future pan-PI3K inhibitors that equally
and specifically inhibit p110a and p110b would be similarly
advantageous.
Since p110b-dependent PIP3 activation in the BYL719-
treated PIK3CA mutant cancers did not lead to a rebound of
AKT activation, it remains unknown which PIP3-dependent sig-
nals affect cell viability in these cells. We attempted to address
this question using an unbiased mass spectrometry approach
comparing the phosphopeptides that were differentially modu-
lated by single-agent BYL719 versus the combination of
BYL719 and TGX-221 in MCF7 cells. The results reveal that co-
inhibition of p110a and p110b leads to sustained downregulation
of some intracellular signaling nodes, including downstream ef-
fectors of the mTORC1-signaling pathway (data not shown).
Interestingly, it has recently been demonstrated that SGK3 acti-
vation, which in turn can activate mTORC1-pathway, can be
partially triggered by a pool of PIP3 that acts independently of
AKT (Bago et al., 2014). However, it remains unknown which of
these pathways are most responsible for driving the p110b-me-
diated effects on cell viability.
The precise mechanism of how p110b is recruited and acti-
vated in cancer is still uncertain; however, it has been sug-
gested that it can occur through GPCRs (Dbouk et al., 2012).
Indeed, we observed that input from both RTKs and GPCRs
is necessary for p110b activation in PIK3CAmutant cells. These
findings are consistent with recent data from Backer and col-
leagues demonstrating that there is synergistic activation of
p110b by concomitant binding to both the Gbg subunit and
phosphotyrosine peptides (Dbouk et al., 2012). In contrast,
the observation that pertussis toxin treatment did not affect
p110b-dependent AKT phosphorylation in HER2-amplified can-
cer cells, whereas lapatinib and LJM716 abolished it, suggests
that the input from GPCRs is dispensable for activation of
p110b-dependent signaling in these cells. However, it is
possible that GPCRs that are not inhibited by pertussis toxin
may contribute to activation of p110b in HER2-amplified cells.
These findings raise the question why GPCRs may not be
necessary to engage p110b in HER2-amplified cells. Since
HER2-amplified cells have dramatically increased HER2/
ERBB3 activation in comparison to PIK3CA mutant cells, we
speculate that the RTK component might be sufficient to induce
p110b activation in HER2-amplified cancers. In PIK3CA mutant(E) Cells were treatedwith single agent or combination of BYL719 (1 mM), LJM716 (
the indicated combination for 24 hr and PIP3 and PI(4,5)P2 levels were quantified
(F) Cells were treated with BYL719 (1 mM), TGX-221 (1 mM), or pertussis toxin (PTX
were quantified by ELISA. p < 0.05 by Student’s t test.
All error bars in this figure represent ± SEM. See also Figure S4.cells, our findings demonstrate that different RTKs, specifically
ERBB3 for T47D and IGF1R for MCF7, work in concert with
GPCRs to recruit and activate p110b. Future studies on clinical
specimens will be required to identify if RTKs other than
HER2/ERBB3 and IGF1R commonly activate p110b signaling
in PIK3CA mutant breast cancers following treatment with
p110a specific inhibitor. These data may inform combination
therapies that might be most effective in PIK3CA mutant breast
cancers.
Our data also raise the related question as to why PIP3 levels
correlate with AKT phosphorylation in HER2-amplified but not in
PIK3CA mutant breast cancer cells. It has been previously re-
ported that specific pools of PIP3 do not correlate with phos-
pho-AKT in some cellular contexts (Mandl et al., 2007), and
that some PIK3CA mutant breast cancers with low phospho-
AKT levels are more reliant on AKT-independent PI3K effectors
(Vasudevan et al., 2009). The PH domain of AKT has a relatively
low affinity for PIP3 in comparison to other PH domains (Park
et al., 2008), thus AKTmembrane localization and activation crit-
ically depends on elevated and localized PIP3 levels. We specu-
late that, in HER2-amplified cells, HER2 is highly localized in
membrane rafts (Pickl and Ries, 2009), and the recruitment
and activation of p110b by HER2/ERBB3 heterodimers following
BYL719 treatment produces highly concentrated local pools of
PIP3, leading to potent activation AKT. However, in PIK3CAmu-
tants, the receptors (RTKs and GPCRs) responsible for p110b
activation may be more diffuse on the membrane, producing
less concentrated local pools of PIP3, which are insufficient to
activate AKT. In this scenario, proteins with PH domains that
have higher affinities for PIP3 than AKT can be activated by the
lower concentrations of local PIP3 produced by p110b. There-
fore, the mechanism of p110b activation may contribute to the
disconnection between PIP3 levels (and thus PI3K activity) and
AKT activation in PIK3CA mutant breast cancers.
Importantly, AKT phosphorylation is currently used as surro-
gate marker to assess PI3K activity both in preclinical and clin-
ical studies. This approach is useful and feasible with available
standard techniques; however, measuring only AKT phosphor-
ylation may risk potentially missing important information by
oversimplifying the PI3K signal transduction pathway. The
data in this work support the notion that direct and comprehen-
sive methods are needed to evaluate PI3K activity and investi-
gate its functions. Thus, in this study we evaluated PI3K activity
by measuring PIP3 levels, and thereby elucidated the benefit of
combining p110a and p110b inhibitors to more efficiently block
PI3K-dependent oncogenic signaling in ‘‘p110a-driven’’ breast
cancers.EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
BT474 and MCF7 cells were cultured in Dulbecco’s modified Eagle’s medium
with 10% fetal bovine serum (FBS). T47D, SKBR3, and AU565 cells wereLJM) (10 mg/ml), NVP-AEW541 (AEW) (1 mM), or NVP-BGJ398 (BGJ) (250 nM) or
by ELISA. p < 0.05 by Student’s t test.
) (100 ng/ml) or the indicated combination for 24 hr and PIP3 and PI(4,5)P2 levels
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Figure 5. Combined p110a and p110b Inhi-
bition Leads to Tumor Regression In Vivo
(A) Waterfall plot showing the percent change in
tumor volume (relative to initial volume) for indi-
vidual BT474 tumors in tumor-bearingmice treated
with the vehicle (VHL), BYL719 (BYL) 25 mg/kg per
oral gavage daily, KIN-193 (KIN) 20 mg/kg per IP
injection twice per day, and combination (BYL/KIN)
groups following 21 days of treatment.
(B) Mice harboring BT474 tumors were adminis-
tered with vehicle (VHL), BYL719 (BYL) 25 mg/kg,
KIN-193 (KIN) 20 mg/kg, or the combination of
BYL/KIN for 3 days. Mice were killed 12 hr after
the last treatment with BYL719 and 2 hr after
treatment with KIN-193. For the combination-
treated mice, tumors were also collected 12 hr
after treatment with BYL719 and 2 hr after KIN-
193. Lysates were prepared from tumors and
blotted with the indicated antibodies.
(C) Tumor growth assay showing the antitumor
effect of BYL719 25 mg/kg per oral gavage daily
and GSK2636771 30 mg/kg per oral gavage daily
alone or in combination on endogenous NeuT tu-
mors. p < 0.05 by two-way ANOVA. The average
tumor volume ± SEM for each cohort is displayed.
(D) Waterfall plot showing the percent change in
tumor volume ofMCF7 xenografts (relative to initial
volume) for individual tumors treated as in (A).
(E) Mice harboring MCF7 were administered as in
(B). Mice were killed 2 hr after the last treatment
with BYL719 and/or KIN-193. Lysates were pre-
pared and blotted with the indicated antibodies.
(F) Phospholipids were isolated from the same
tumors as (E) and PIP3 and PI(4,5)P2 levels were
quantified by ELISA. Each data point is the
average ± SEM (p < 0.05 by Student’s t test).
See also Figure S5.
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PIP3 Levels Reveal p110b Role in Breast Cancercultured in RPMI1640 with 10% FBS. KPL-1 and BT-20 cells were cultured in
DF12 with 10% FBS. Cell lines were obtained from the Center for Molecular
Therapeutics atMassachusetts General Hospital Cancer Center. The following
drugs were used: TGX-221 (Selleckchem), Lapatinib (LC laboratories and Ab-
mole), GDC-0941 (supplied by the Targeting PI3K in Women’s Cancers Stand
Up to Cancer Dream Team), AZD8055 (Selleckchem), IC87114 (Selleckchem),
BYL719 and LJM716 (kindly provided by Novartis), KIN-193 (kindly provided
by Jean Zhao), GSK2636771 (Abmole), NVP-BGJ398 (Selleckchem), NVP-
AEW541 (Selleckchem), and MK2206 (Selleckchem).
Immunoblotting
Antibodies against p-AKT (Ser 473), p-AKT (Thr 308), p110a, p110b, p-GSK3a/
b, p-PRAS40, p-ATP citrate lyase, p-ERBB3, p-HER2, HER2, PARP, ACTIN,
IR, IGFR, FGFR1, p-RPS6 (Ser240-244), p-Tyrosine, and PTEN were from
Cell Signaling Technology. Antibodies against AKT and ERBB3 were pur-
chased from Santa Cruz Biotechnology. GAPDH, IRS1, and p85 antibodies
were from Millipore.
Small Interfering RNA Knockdown
Cells were seeded into six-well plates at density of 1.5 3 105 cells/well.
Twenty-four hours later, cells were transfected with ON-TARGETplus SMART-
pool siRNA against p110b (Dharmacon), ERBB3 (Ambion), or ON-TARGET
plus Nontargeting Pool as negative control using HiPerFect transfection re-
agent (QIAGEN) according to the manufacturer’s instructions. Transfected
cells were cultured at 37C for 72 hr before analysis.
HPLC Phosphoinositide Analysis
Cells were metabolically labeled with 10 mCi/ml [3H] inositol for 48 hr in
inositol-free DMEM supplemented with dialyzed fetal calf serum (GIBCO)
and 200 mM L-glutamine. After the cells were labeled, they were treated106 Cancer Cell 27, 97–108, January 12, 2015 ª2015 Elsevier Inc.as indicated and lysed in 1 N HCl. Lipids were extracted in chloroform-meth-
anol (1:1, vol/vol). Phosphoinositides were separated by anion-exchange
HPLC (Beckman), detected by a flow scintillation analyzer (Perkin-Elmer),
and quantified using ProFSA software (Perkin-Elmer) as described previously
(Mandl et al., 2007).
PIP3/PI(4,5)P2 Quantification
Cells were seeded at density of 1 3 107 cells/10 cm dish. After treatment, the
media was removed by aspiration and 5 ml of ice-cold 0.5 M TCA was imme-
diately added. Cells were scraped, transferred into a 15 ml tube on ice, and
centrifuged at 3,000 revolutions per minute (rpm) for 7 min at 4C. The pellet
was resuspended in 3 ml of 5% tricarboxylic acid/1 mM EDTA, vortexed,
and centrifuged at 3,000 rpm for 5 min, the supernatant was discarded, and
this washing step was repeated one more time. Afterward, neutral lipids
were extracted adding 3 ml of MeOH:CHCl3 (2:1) and continuously vortexing
over 10 min at room temperature. Extracts were centrifuged at 3,000 rpm
for 5 min, the supernatant was discarded, and this extraction step was
repeated one more time. The acidic lipids were extracted adding 2.25 ml
MeOH:CHCl3:12 M HCl (80:40:1) with continuous vortexing over 25 min at
room temperature. Extracts were centrifuged at 3,000 rpm for 5 min and the
supernatant was transferred to a new 15 ml tube; 0.75 ml of CHCl3 and
1.35ml of 0.1MHCl were added to the supernatant, vortexed, and centrifuged
at 3,000 rpm for 5 min to separate organic and aqueous phases. The organic
(lower) phase was collected; 1.45 ml were transferred into new vial for PIP3
measurement and 0.05 ml were transferred into a new vial for PI(4,5)P2 mea-
surement. All samples were dried in a vacuum dryer for 1 hr. PIP3 samples
were resuspended in 120 ml of PBS-Tween+3% Protein Stabilizer (provided
by the Echelon kit). PI(4,5)P2 samples were re-suspended in 120 ml of PBS+
0.25% Protein Stabilizer. Samples were sonicated in an ice-water bath for
10 min, vortexed, and spun down before adding to the ELISA. All experiments
Cancer Cell
PIP3 Levels Reveal p110b Role in Breast Cancerwere performed at least three times, each carried out in biological triplicate.
Once phospholipids were isolated from cells, PIP3 and PI(4,5)P2 levels were
measured using ELISA kits (Echelon, K-2500s and K4500) according to the
manufacturer’s instructions.
Apoptosis Analysis
Cells were seeded at 30%–40% confluence in 6 cm plates. After overnight
incubation, media was aspirated and replaced with media with or without indi-
cated drugs. After 72 hr, media was collected. Cells were harvested, rinsed
once with PBS, and resuspended in Annexin binding buffer (BD Biosciences).
Cells were stained with propidium iodide (BD Biosciences) and Annexin V Cy5
(Biovision) according to the manufacturer’s protocol and analyzed on a LSRII
flow cytometer (BD Biosciences).
Viability Assays
Three thousand cells were seeded in quadruplicate in 24 wells and treatedwith
fresh media and drug every 72 hr. At day 14, cells were washed with PBS and
fixed in 4% formaldehyde for 20 min. Then, cells were washed twice with
dH20, and stained for 1 hr with Syto60 (Invitrogen). The plates were then
read bymeasuring the absorption at 700 nmwith the Odyssey Imaging System
(LI-COR). For CellTiter-Glo assay (Promega) 5,000 cells were seeded in tripli-
cate in 96wells and the following day treatedwithmedia or drug. At day 3, 50 ml
of CellTiter-Glo was added to each well and the plate was read on a Centro LB
960 microplate luminometer (Berthold Technologies) according to the Prom-
ega protocol.
BYL719 Screening Sensitivity
Theassaywasperformed in96-well plates, andeach treatmentwasdone in trip-
licate. Every cell line was treated with 2 mMBYL719 as well as DMSO as a con-
trol. After 72 hr of drug treatment, cells were stained with the fluorescent dye
Syto60. The viability ratio was obtained by [average fluorescence read of
2mMBYL719-treatedcells]/[averagefluorescence readofDMSO-treatedcells].
Xenograft Mouse Studies
For xenograft experiments, femalemicewere implanted with estrogen 0.72mg
of 17b-estradiol pellets (Innovative Research of America). A suspension of 15–
20 3 106 cells was inoculated subcutaneously into the left flanks of 6- to 8-
week-old female athymic nude mice. Tumors were monitored until they
reached approximately the average size of 250–400 mm3. At this time, mice
were randomized to control and treatment groups (n = 6 per group). BYL719
was dissolved in 0.5% carboxymethyl cellulose sodium salt (Sigma) and
administered at 25 mg/kg once a day by oral gavage. KIN-193 was dissolved
in 7.5% NMP (Sigma), 40% PEG400 (Sigma), 52.5% dH2O, and given by IP in-
jection twice a day at 20 mg/kg. Tumors were measured twice weekly using
calipers. For pharmacodynamic analyses, tumor-bearing mice were adminis-
tered with drugs or vehicle for 3 days. Tumor tissue was excised and snap-
frozen in liquid nitrogen for immunoblotting or phosphoinositidemeasurement.
Virgin female BALB-neuT mice transgenic for the rat-transforming neu onco-
gene expressed under the control of mouse mammary tumor virus promoter
(Ciraolo et al., 2008) were weekly monitored for mammary tumor development
by palpation. Once palpable tumors were present, tumor size was measured
twice a week using a caliper. Treatments were initiated when a cumulative
tumor burden of around 25 mm3 was reached, at which point mice were ran-
domized into four groups of five mice each. GSK2636771 was dissolved on
0.5% metilcellulose and 0.2% Tween 80. Mice were daily treated by oral
gavage with GSK2636771 (30 mg/kg), BYL719 (25 mg/kg), or a combination
of the two drugs for 21 days. The combo mice received the two treatments
30 min apart. The final group of animals was treated with vehicles of both
agents. All mice were killed using CO2 inhalation per institutional guidelines
at Massachusetts General Hospital or University of Torino. Experiments
were approved by the Institutional Animal Care and Use Committee at Massa-
chusetts General Hospital or University of Torino.
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